# BPC-157 TB-500 Dosage: Research-Model Parameters, Routes, and Half-Life | Wolverine Order > BPC-157 TB-500 dosage in the research literature: animal-model doses for each constituent, routes studied, reconstitution context, and the fact that no validated human or blend dose exists. These are the doses, routes, and durations used in animal models and the few single-agent human studies. There is no validated human dose for either peptide, and none at all for the blend. ## BPC-157 and TB-500 Dosing Parameters in the Research Literature BPC-157 TB-500 dosage has no validated human answer, and it is important to say that before any number. There is no validated dose for the blend, and commercial vials that pair the two at a fixed combined mass (for example, roughly 10 mg of each per vial) reflect packaging, not a dose-finding study [8]. What follows are [BPC-157 and TB-500 dosing parameters](/dosage) as they appear in the research record — described as "studied at X in [species]," never as guidance. For the BPC-157 component, rodent studies commonly express dose per body weight, frequently around 10 microg/kg and 10 ng/kg; gastric-ulcer cytoprotection has been studied at 400-800 ng/kg in rats [5]. For the TB-500 / Thymosin Beta-4 component, the range is wide: a rat embolic-stroke dose-response study used 2-18 mg/kg intraperitoneally, modeled an optimum near 3.75 mg/kg, and — importantly — found that 18 mg/kg gave no benefit, so higher is not better [7]. In the mdx muscular-dystrophy model, Thymosin Beta-4 was given at 150 microg twice weekly intraperitoneally for six months [7]. Human reference points exist only for full-length Thymosin Beta-4, not the blend: intravenous Thymosin Beta-4 was well tolerated up to 1260 mg in a Phase 1 study [7]. Community "loading then maintenance" blend protocols have no controlled-trial basis [8]. ## Half-Life and Pharmacokinetics ### What is the half-life of BPC-157 and TB-500? No validated human half-life exists for either constituent or the blend. BPC-157's elimination half-life was reported as under 30 minutes in a rat and dog pharmacokinetic study; human intravenous Thymosin Beta-4 showed dose-proportional pharmacokinetics, but no specific half-life is established for the TB-500 heptapeptide [7]. You can read the broader [half-life and pharmacokinetics](/dosage#pharmacokinetics) context here. The practical upshot is that the blend has no characterized pharmacokinetic profile at all. Two peptides with very different sizes (about 1419 Da and about 889 Da) and no joint study means the timing assumptions behind community dosing schedules are guesses, not data. ## Oral vs Injectable Routes in BPC-157 and TB-500 Research ### BPC-157 TB-500 oral and injectable routes BPC-157 is studied as a "stable gastric" peptide, and oral and peroral routes appear in its individual literature; blend oral products are marketed but lack validated pharmacokinetics [8]. Across the underlying rodent efficacy studies, the predominant route for both peptides was intraperitoneal [5][7]. Human single-agent work used intravenous routes (the Thymosin Beta-4 Phase 1 and a BPC-157 intravenous safety pilot), and individual-compound wound and tendon models also used local, intra-lesional, and topical routes [7]. The honest summary: BPC-157's gastric stability is a genuine feature of its own research, but there is no validated oral pharmacokinetic profile for the blend, and combining a peptide studied orally with one studied by injection does not make the pair an oral product. ## Administration, Reconstitution, and Cycling ### How the Wolverine Blend Is Administered in Research Settings In research-community handling, the Wolverine blend is described as administered subcutaneously or intramuscularly — routes that come from community practice, not controlled human efficacy trials [8]. The underlying rodent efficacy studies used the intraperitoneal route for both peptides [5][7]. This is research context, not a human-use instruction. ### Reconstitution in Research Handling Both constituents are supplied as lyophilized powders for research use, reconstituted in bacteriostatic or sterile water and refrigerated [8]. Product identity, purity, and the actual BPC-157-to-TB-500 ratio in unregulated material are not guaranteed — a caveat that compounds the existing TB-500 identity question (fragment versus full-length Thymosin Beta-4) [8]. This is research-handling context, not a human-use instruction. ### Administration Frequency in Research Protocols There is no validated injection schedule for the blend. Underlying rodent studies used a range of dosing — for example, Thymosin Beta-4 at 150 microg twice weekly intraperitoneally for six months in one model [7] — and community "loading then maintenance" protocols have no controlled-trial basis [8]. ### Cycling in Research Discussions No validated cycle exists. Community "loading then maintenance" blend protocols and fixed-ratio vials (for example, 10 mg plus 10 mg) have no basis in controlled human trials and should not be presented as validated dosing [8]. Underlying study durations vary widely by model. --- A soft pastel reading-room for the BPC-157 and TB-500 record — each peptide read kindly against its own studies, the missing blend trial left plainly unfilled, and the FDA 503A status set out gently; nothing is dispensed and nothing is sold here.